Retina

Professor Alió reflects on a new comprehensive volume dedicated to aging in ophthalmology

According to the company, the NDA submission is supported by data from the phase 3 DRAGON trial.

Temporal optical coherence tomography modelling may improve longitudinal disease tracking.

Phase 3 data show brolucizumab outperforms laser for PDR vision preservation, with fewer adverse events—while monitoring inflammation risk.

The dual-function phaco-vitrectomy platform is cleared for European commercialization, with launch targeted for Q3 2026.

Zaman discusses the positive topline results from a phase 1/2 study of the BIM-IOL system, during which it successfully reduced IOP in patients with OAG or OHT.

The decision lengthens the approved treatment period outlined in the prescribing information and may lessen the need to change therapies for patients who continue to show a lasting response.

Images showed that Parkinson’s disease is associated with a thicker photoreceptor nuclear layer and a thinner layer of photoreceptor processes.

Study finds low-vision rehab boosts daily function and quality of life, but exposes gaps in long-term data and diverse research.

The ongoing GARDian3 study is designed to assess whether a single subretinal administration of OCU410ST can slow structural disease progression in patients with ABCA4-associated retinopathy.

Kodiak Sciences has indicated plans to submit a biologics license application (BLA) to the US Food and Drug Administration.

Q1 2026 eye-care roundup: first dual-agent presbyopia drop, new EDOF IOL, wet AMD phase 3 win, and gene-therapy advances.

Luminopia, formerly cleared by the FDA for amblyopia in children, has begun its foray into IXT with positive data from a preliminary investigation.

Key regulatory filings, phase 3 readouts, and trial enrollments to watch through June 30.

New MLSDT functional vision test tracks advanced retinitis pigmentosa better than acuity, supporting future gene and optogenetic therapy endpoints.

DSP-3077 is being evaluated by Sumitomo Pharma in an ongoing phase 1/2 study (NCT06891885), designed to assess safety, tolerability, and preliminary efficacy in patients with RP.

Prof. Sobha Sivaprasad discusses why GA's multistage nature demands a broader therapeutic approach—and what evidence will shape clinical decision-making.

Prof. Anat Loewenstein questioned whether treat-and-extend will remain the preferred strategy as longer-acting therapies emerge.

Aflibercept briefly reverses severe ROP in tiny preemies, yet nearly half relapse within weeks—prompting laser rescue and renewed safety questions.

See which ophthalmology surgery centers earn US News’ 2026 high-performing badge, where they cluster, and why complication rates drop 40%.

The trial, sponsored by ONL Therapeutics, aims to enrol approximately 324 patients across sites in Europe, the United States, and Canada.

About 90% of patients are female with obesity and potential hormonal drivers